Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK5 | P34947 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2014924 | 0.84 | KMT2A (0.40) | GRK5ALDH1A1TDP1 | |
| SCHEMBL12575450 | 0.80 | GRK5 (0.60) | GRK5GAACYP11B2CYP11B1NT5E | |
| SCHEMBL2020736 | 0.71 | MET (0.54) | GRK5ALDH1A1TDP1KDR | |
| SCHEMBL24871111 | 0.70 | CYP2A6 (0.68) | CYP11B2CYP11B1CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL999865 | 0.70 | CYP2A6 (0.68) | CYP11B2CYP11B1CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL17223083 | 0.68 | CYP2A6 (0.54) | CYP11B2CYP11B1CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL13907273 | 0.68 | CYP2A6 (0.88) | CYP11B2CYP11B1CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL29360677 | 0.68 | CYP2A6 (0.88) | CYP11B2CYP11B1CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL24534338 | 0.68 | CYP2A6 (0.88) | CYP11B2CYP11B1CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL10035319 | 0.66 | AVPR1A (0.56) | CYP11B2CYP11B1CYP2A6CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343977-B2 | Substituted triazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343977-B2 | Substituted triazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343977-B2 | Substituted triazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2011082271-A2 | SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160226-A1 | Substituted Triazolo-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160226-A1 | Substituted Triazolo-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160226-A1 | Substituted Triazolo-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160226-A1 | Substituted Triazolo-Pyrimidine Compounds | TYMP, TK1, DPYD | GRK5 557/4885GAA 1386/4885CYP11B2 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.